Adverum Biotechnologies, Inc. announced an extension of its collaboration agreement with Editas Medicine, Inc. The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases. Under the terms of the extended agreement, Adverum and Editas are extending the research period through third quarter of 2018. Editas maintains a series of options exercisable between now and August 2020.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.13 USD | +4.24% |
|
+2.15% | -5.29% |
07-01 | Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell Small Cap Comp Value Index | CI |
07-01 | Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell Small Cap Completeness Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.29% | 148M | |
+15.58% | 121B | |
+16.60% | 110B | |
+17.73% | 25.93B | |
-24.33% | 19.27B | |
-19.35% | 16.01B | |
-17.95% | 15.66B | |
-48.32% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- ADVM Stock
- News Adverum Biotechnologies, Inc.
- Adverum Biotechnologies and Editas Medicine Extend Research Collaboration